A new drug has been approved by the Food and Drug Administration (FDA) for a rare, inherited form of amyotrophic lateral sclerosis (ALS), a paralyzing neurological disease. Known as tofersen, the drug has been shown to slow progression of the deadly disease. International clinical trials of tofersen, developed by the global biotechnology company Biogen Inc., […]
An investigational drug developed to treat a rare, inherited form of amyotrophic lateral sclerosis (ALS) reduced molecular signs of the fatal, paralyzing disease and curbed neurodegeneration — but at the six-month mark, the drug did not improve motor control and muscle strength, according to results from a phase 3 clinical trial led by researchers at […]
Drug extends survival, reverses some neuromuscular damage in animals From the WashU School of Medicine News… About 20,000 people in the United States are living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The invariably fatal disease kills the nerve cells that control walking, eating and breathing. Few people survive more than […]